ROHHAD syndrome is an extremely rare childhood disorder in which a previously healthy child develops rapid, dramatic weight gain followed by breathing problems during sleep, hormonal dysfunction, and failures of the body’s automatic control systems. The name is an acronym: Rapid-onset Obesity with Hypoventilation, Hypothalamic dysfunction, and Autonomic Dysregulation. Fewer than 200 cases have been documented worldwide, and because the condition is so uncommon, it is frequently misdiagnosed or recognized only after a life-threatening event.
How the Acronym Breaks Down
Each letter in ROHHAD points to a specific cluster of problems that appear over time:
- Rapid-onset Obesity (RO): A child who had been growing normally suddenly gains a large amount of weight, typically between ages 2 and 7. The weight gain is striking and does not respond to normal dietary changes.
- Hypothalamic dysfunction (H): The hypothalamus, a small region of the brain that manages hormones, body temperature, thirst, and puberty timing, begins to malfunction. This can show up as an underactive thyroid, abnormally early or late puberty, growth hormone deficiency, or problems regulating water balance in the body (a condition called diabetes insipidus, unrelated to the more common diabetes).
- Hypoventilation (H): The child’s breathing becomes dangerously shallow during sleep. The brain essentially “forgets” to tell the lungs to breathe deeply enough, allowing carbon dioxide to build up in the blood. This is one of the most dangerous features of the syndrome and can lead to respiratory arrest.
- Autonomic Dysregulation (AD): The autonomic nervous system, which controls unconscious body functions, starts to fail. Signs include abnormal body temperature (running too hot or too cold), an unusually slow heart rate, irregular blood pressure, excessive or absent sweating, severe constipation, and changes in pupil size or eye movement.
How Symptoms Unfold Over Time
One of the defining features of ROHHAD is that children appear completely healthy for the first few years of life. There are no signs at birth, no developmental delays in infancy, and no red flags during routine checkups. The rapid weight gain is almost always the first symptom to emerge, usually between ages 2 and 7, and it tends to be the reason parents seek medical attention.
Hormonal problems typically follow the obesity, sometimes within months. The breathing abnormalities often come later, which creates a dangerous diagnostic gap. A child may carry the condition for years before hypoventilation develops, and without monitoring, the first sign of a breathing problem can be a sudden cardiorespiratory arrest. Autonomic symptoms can appear at any point and tend to accumulate over time.
The Tumor Connection
About 40% of children with ROHHAD also develop tumors of the nervous system, most commonly ganglioneuromas or ganglioneuroblastomas found in the abdomen, chest, or near the adrenal glands. Because of this association, the condition is sometimes referred to as ROHHAD-NET (neuroendocrine tumor). These tumors are generally slow-growing and often benign, but in rare cases neuroblastomas (a more aggressive type) have been reported. Imaging of the chest and abdomen is a standard part of monitoring once a diagnosis is suspected.
What Causes It
The honest answer is that no one knows yet. No specific gene has been identified as the cause, which makes ROHHAD different from a similar-looking condition called congenital central hypoventilation syndrome (CCHS). CCHS is caused by a mutation in the PHOX2B gene. Children suspected of having ROHHAD are tested for that mutation, and a negative result is actually required to confirm the ROHHAD diagnosis.
There is growing interest in the possibility that ROHHAD has an autoimmune or immune-inflammatory basis. In one published case, a five-year-old girl who presented in respiratory arrest after six months of rapid weight gain was found to have elevated levels of a key inflammatory marker (interleukin-6). After treatment with an immune-suppressing medication, her inflammatory markers normalized and her weight dropped from well above the 99.6th percentile to the 50th percentile within 12 months. That is a single case, not a proven treatment, but it suggests the immune system may play a central role in driving the disease.
How It Differs From Similar Conditions
ROHHAD is most commonly confused with two other conditions: Prader-Willi syndrome and CCHS.
Prader-Willi syndrome also causes childhood obesity, but the trajectories are different. Children with Prader-Willi show problems from birth: low muscle tone, weak cry, feeding difficulties in infancy. They never have the normal, healthy first years of life that define ROHHAD. Genetic testing for the Prader-Willi chromosomal region can rule it out definitively.
CCHS shares the shallow breathing during sleep and autonomic dysfunction seen in ROHHAD, but it lacks the hypothalamic problems (hormonal disruption, rapid weight gain). The clearest dividing line is genetic: CCHS is defined by a PHOX2B mutation, and ROHHAD patients do not carry it. Without that genetic test, the two conditions can look nearly identical at the bedside.
How ROHHAD Is Managed
There is no cure for ROHHAD. Treatment focuses on managing each symptom to prevent life-threatening complications, and it requires a team spanning pulmonology, endocrinology, oncology, and neurology.
The most critical piece is supporting breathing during sleep. Historically, many children received a tracheostomy for mechanical ventilation. Increasingly, noninvasive options like bilevel positive airway pressure (a mask-based breathing device similar to a CPAP) are used, especially when the hypoventilation is caught before it becomes severe. Sleep studies are repeated every three to six months to track whether breathing is worsening and to adjust ventilator settings. Adequate ventilation during sleep can also improve daytime breathing and slow disease progression.
Hormonal problems are treated individually as they arise. A child with an underactive thyroid takes thyroid hormone replacement. Growth hormone deficiency, diabetes insipidus, and abnormal puberty timing each have their own standard treatments. Autonomic symptoms like temperature instability and blood pressure swings are harder to manage and often require careful, ongoing monitoring rather than a single fix.
If a tumor is found, surgery to remove it is typically recommended, followed by regular imaging to check for recurrence.
Prognosis and Long-Term Outlook
ROHHAD is a serious, life-shortening condition. The greatest risk is respiratory or cardiac arrest, which can occur suddenly if hypoventilation goes unrecognized or is inadequately treated. At least 16 documented deaths have been attributed to respiratory failure, cardiac complications, or aggressive tumors. Because the condition is so rare, large-scale survival data do not exist, and outcomes vary widely depending on how early the diagnosis is made and how well breathing support is maintained.
Early recognition is the single most important factor in improving outcomes. Children who are diagnosed before a cardiorespiratory crisis and placed on appropriate ventilatory support have a meaningfully better chance of long-term survival and quality of life. The challenge is that the early symptoms, particularly rapid weight gain in a young child, are common enough to be attributed to diet or other causes, and the rarer features may not appear for months or years afterward.